Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Coherus Oncology, Inc.

NASDAQ: CHRS · Life Sciences · 3 alerts · CIK 1512762

Share price
$0.5059Close, Nov 16
Market cap
$78.2M
Shares outstanding
154.54MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Coherus Oncology, Inc. filings on SEC EDGAR ↗

8:10 AM ET 8-K
Clinical Trial Data

Coherus Oncology Clinical Trial Data

Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in combination with toripalimab for esophageal squamous cell carcinoma (ESCC). The study reported a 75% confirmed overall response rate (cORR) in first-line ESCC patients irrespective of PD-L1 status, which increased to 89% following the data cutoff. The results provide clinical proof-of-concept for tagmokitug and support the expansion of enrollment in both first-line and second-line ESCC cohorts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.